Product Description
DW1330 is associated with the mechanism of glycemic control and inflammation pathways
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Taiwan Resonant Waves Research
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03102424 |
TRWRDM1604001 | N/A |
Completed |
Type 2 Diabetes |
2020-07-15 |
2021-04-02 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|